Market focus
Healthcare + regulated edge AI
Investors
Funding the next engineering milestone for Medi AI+.
Provenant AI Labs is advancing Medi AI+ from a completed engineering proof-of-concept toward an integrated TRL 4 laboratory prototype, combining local speech intelligence, governed medical knowledge, multimodal clinical context and deterministic human-supervised safety on edge hardware.
Current objective
TRL 3 → TRL 4 prototype validation
Proof base
Patent + public technical research
Launch base
Singapore-first validation
Current Financing Objective
S$200k Prototype & Validation Round
Advance Medi AI+ from TRL 3 engineering proof-of-concept toward TRL 4 integrated laboratory validation.
Edge Hardware
Representative edge compute and peripherals.
AI Adaptation
Medi Speech and Medi Knowledge.
Integration
Core platform and interoperability.
Validation
Safety, performance and engineering verification.
Target outcome: Integrated laboratory-validated Medi AI+ prototype suitable for progression toward institutional evaluation. This round does not imply institutional or clinical validation will be completed from this funding alone.
Investment thesis
Cloud-dependent AI does not fit every privacy-sensitive or connectivity-constrained environment.
Local AI appliances create a deployment model buyers can evaluate through infrastructure, governance, and support.
Healthcare institutions need human-supervised, audit-ready AI workflows rather than generic chatbot tooling.
Singapore provides a credible launch base for regulatory-readiness, clinical stakeholder review, and regional expansion.
Investor notice
This website is not an offer to sell securities, a solicitation to buy securities, or investment, legal, tax, or financial advice. Investor materials are provided only after appropriate review and, where applicable, only to persons who satisfy relevant qualification, accreditation, or exemption requirements under applicable law. In India, this page is not a public offer, private placement invitation, prospectus, placement memorandum, or solicitation under the Companies Act, SEBI regulations, or other securities laws. Any India investor discussion is subject to prior legal review and applicable eligibility requirements.
Investor enquiry
Investor materials are shared selectively with qualified parties after introductory review.
View Technical Brief View Engineering Status